Prophylactic antibiotic receives speedy FDA approval to reduce MAC disease in advanced HIV.
D017088:AIDS-Related Opportunistic Infections / Q000188:drug therapy*; D000900:Anti-Bacterial Agents / Q000627:therapeutic use*; D000904:Antibiotics, Antitubercular / Q000627:therapeutic use; D017963:Azithromycin / Q000627:therapeutic use*; D017277:Drug Approval; D004359:Drug Therapy, Combination; D006801:Humans; D015270:Mycobacterium avium-intracellulare Infection / Q000188:drug therapy*; D017828:Rifabutin / Q000627:therapeutic use; D014481:United States; D014486:United States Food and Drug Administration
D000900:Anti-Bacterial Agents; D000904:Antibiotics, Antitubercular; D017828:Rifabutin; D017963:Azithromycin